Lecture Presentation: Neal Shore: Hello, and welcome to our program today. This is one of a series of modules, “Precision Medicine PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Educational Forum”. We’re really pleased today to have an outstanding faculty, Dr. Oliver Sartor, who is going to discuss the VISION trial, which I know we’ve […]
Lecture Presentation: Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU medical oncologist and Associate Professor of Medicine at Northwestern University. I’m so delighted to have you here today to talk about precision medicine, PSMA-targeted therapies, and progressive metastatic prostate cancer, in educational forum. Today we’re going to talk to two really […]
First and only FDA-approved immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III study In JAVELIN Bladder 100, BAVENCIO maintenance treatment extended median overall survival by 50% over standard of care Priority review completed under FDA’s Real-Time Oncology Review (RTOR) pilot program, following receipt of Breakthrough Therapy Designation […]
When docetaxel first emerged on the prostate cancer scene, the world celebrated our first agent that offered an overall survival benefit for patients with metastatic castration-resistant prostate cancer.1,2 Although, there are now many more agents regulatory approved for metastatic castration-resistant prostate cancer, docetaxel remains an important “tool in our toolbox” in our attempts to improve […]
{{header-clinical-trials-navigation}} A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC) Condition: Metastatic Castrate Resistant Prostate Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03737370 Sponsor: Tufts Medical Center Phase: Phase 1 Eligibility: Age: minimum 18 Years maximum N/A Gender: All Inclusion Criteria: Histologically or cytologically confirmed adenocarcinoma […]
Lymph node involvement in renal cell carcinoma (RCC) correlates with poor oncologic outcomes. However, current RCC staging guidelines may not fully reflect the survival impact of lymph node positive disease.
Metastatic renal cell carcinoma (mRCC) encompasses a heterogeneous group of neoplasms with distinct clinical behavior and prognoses. As a result of the increasing number of therapeutic options in the metastatic setting, it is crucial to improve prognostic stratification ability.
Although salvage external-beam radiation therapy (EBRT) is an attractive treatment option for pelvic lymph nodal recurrence (PeNR) in patients with prostate cancer (PCa), limited data are available regarding its long-term efficacy.
Purpose: Existing questionnaires assessing sexual function after prostate cancer (PCa) were developed in predominantly heterosexual male cohorts and may measure function incompletely in gay men.
Perirectal spacers are intended to lower the risk of rectal toxic effects associated with prostate radiotherapy. A quantitative synthesis of typical clinical results with specific perirectal spacers is limited.
